Hannah Green interviewed our CEO, Dan Mandell, PhD, about how GRObio’s ProGly-NSAAs prevent immune reactions that render many therapies ineffective, and how resolving this critical limitation is key to advancing the Company’s lead asset for treating patients with severe, refractory gout into the clinic.
From the article: “GRObio’s lead drug, which it calls ProGly-Uricase, is intended to treat severe, refractory gout, a type of arthritis caused by a buildup of uric acid. Mandell said one current treatment option is a uricase enzyme, which is designed to break up uric acid crystal deposits and reduce circulating uric acid levels. However, patients’ bodies often develop anti-drug antibodies that remove the enzyme from circulation. GRObio has designed its ProGly NSAAs to include sugar molecules. These NSAAs can teach the immune system to treat the drug as part of the body rather than a foreign protein.”
